Development of malaria vaccines that block transmission of parasites by mosquito vectors.
Malaria is still one of the infectious diseases urgently requiring control and causes socioeconomic burdens on people residing in developing countries. Malaria vaccines are expected to control the disease. However, there is no effective vaccine available despite the intense efforts of malaria scientists. One strategy for a malaria vaccine is to prevent parasite spread by means of interfering with parasite development in mosquito vectors, which is the so-called transmission-blocking vaccine (TBV). We will here review the current progress of TBV.
D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D009033:Culicidae / Q000187:drug effects* / Q000469:parasitology; D005260:Female; D006790:Host-Parasite Interactions; D006801:Humans; D007303:Insect Vectors / Q000187:drug effects*; D008018:Life Cycle Stages; D008288:Malaria / Q000517:prevention & control* / Q000635:transmission; D017780:Malaria Vaccines / Q000276:immunology / Q000494:pharmacology; D010961:Plasmodium / Q000187:drug effects* / Q000254:growth & development / Q000276:immunology; D010966:Plasmodium vivax / Q000276:immunology; D015800:Protozoan Proteins / Q000276:immunology; D012098:Reproduction / Q000276:immunology; D012377:Rodentia; D012469:Salivary Glands / Q000469:parasitology
D000953:Antigens, Protozoan; D000954:Antigens, Surface; D017780:Malaria Vaccines; D015800:Protozoan Proteins; C121473:Pvs25 protein, P vivax